Home > Insider Trading > Filing (0001246360-14-002041)

Filing Details

Accession Number:: 0001246360-14-002041
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-04-03 17:56:08
Reporting Period:: 2014-04-01

Filing Date:: 2014-04-03
Accepted Time:: 2014-04-03 17:56:08
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
911326	Synageva Biopharma Corp	GEVA	Biological Products, (No Disgnostic Substances) (2836)	561808663

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1532219	Anthony Quinn	33 Hayden Ave Lexington MA 02421	Evp, Cmo & Head Of R&D	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-04-01	10,000	$0.95	25,524	No	4	M	Direct
Common Stock	Acquisiton	2014-04-01	10,000	$23.00	35,524	No	4	M	Direct
Common Stock	Disposition	2014-04-01	10,675	$82.80	24,849	No	4	S	Direct
Common Stock	Disposition	2014-04-01	3,529	$83.50	21,320	No	4	S	Direct
Common Stock	Disposition	2014-04-01	4,746	$84.72	16,574	No	4	S	Direct
Common Stock	Disposition	2014-04-01	1,050	$85.76	15,524	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2014-04-01	10,000	$0.00	10,000	$0.95
Common Stock	Stock Option (Right to Buy)	Disposition	2014-04-01	10,000	$0.00	10,000	$23.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
28,964		2019-10-07	No	4	M	Direct
40,000		2021-12-20	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	15,524	Direct

Footnotes

The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 26, 2013.
The Stock Option granted the reporting person an option to purchase 101,080 shares of Common Stock (the "Shares"). 25% of the Shares vested and became exercisable on 08/31/2010, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter.
The Stock Option granted the reporting person an option to purchase 50,000 shares of Common Stock (the "Shares"). 25% of the Shares vested and became exercisable on 12/20/2012, and 1/30 of the remainder of the Shares vest and become exercisable monthly thereafter.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $82.14 to $83.12. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $83.15 to $84.02. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $84.33 to $85.30. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $85.37 to $86.26. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.